1928 diagnostics AB

1928 Diagnostics AB is a bioinformatics company focused on providing advanced genomic data analysis solutions. Their innovative platforms enable rapid, reliable insights for various applications in genomics and microbiome research. Founded in 2014 and headquartered in Gothenburg, Sweden, 1928 Diagnostics AB specializes in bioinformatics solutions. The company has pursued a series of two deals, with the most recent funding occurring on June 29, 2018, when it raised SEK 15 million in venture financing.

The founders, Kristina Lagerstedt and Susanne Staaf, bring experience from previous entrepreneurial ventures in the biotechnology sector. 1928 Diagnostics specializes in delivering innovative bioinformatics solutions that facilitate rapid and reliable analysis of genomic data. The company’s core offerings include platforms for whole genome sequencing, outbreak tracing, 16S/ITS amplicon sequencing, shotgun metagenomics, and custom bioinformatics projects. These solutions are designed to simplify complex bioinformatics tasks, allowing users, regardless of their technical expertise, to manage and derive insights from raw data within minutes.

The targeted customer base includes research institutions, clinical laboratories, and industries focused on genetic analysis and microbiome research. 1928 Diagnostics primarily serves clients in North America, Europe, and select markets in Asia, enhancing their capabilities to produce accurate results while maintaining data security compliant with international standards. In the most recent fiscal year, 2024, 1928 Diagnostics reported a revenue of SEK 153,338. 3, with an EBITDA of SEK -395,629.

8. The revenue model relies on B2B transactions through subscriptions and partnerships with research and clinical organizations, offering access to its proprietary bioinformatics platform. Clients engage with the company through subscription-based pricing tiers, which may include one-time fees for specific sequencing projects or ongoing access to comprehensive analysis tools. 1928 Diagnostics aims to enhance its existing bioinformatics offerings and expand into new geographic markets.

The funding raised on June 29, 2018, will support these initiatives, focusing on product development and market entry strategies. The company plans to launch new products and enhance its current platform features to better serve its clients. Specific new geographic markets targeted for expansion have not been disclosed, but the company is poised to increase its footprint within North America, Europe, and Asia to further enhance its service delivery.